The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA 1 -M2BP) was recently shown to be a liver fibrosis glycobiomarker with a unique fibrosisrelated glycoalteration. We evaluated the ability of WFA 1 -M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA 1 -M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha-fetoprotein (AFP), WFA 1 -M2BP, and the response to interferon (IFN) therapy. Serum WFA 1 -M2BP levels were significantly increased according to the progression of liver fibrosis stage (P < 0.001). In each distinctive stage of fibrosis (F0-F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA 1 -M2BP. Multivariate analysis identified age >57 years, F4, AFP >20 ng/mL, WFA 1 -M2BP 4, and WFA 1 -M2BP 1-4 as well as the response to IFN (no therapy vs. sustained virological response) as independent risk factors for the development of HCC. The time-dependent areas under the receiver operating characteristic curve demonstrated that the WFA 1 -M2BP assay predicted the development of HCC with higher diagnostic accuracy than AFP. Conclusion: WFA 1 -M2BP can be applied as a useful surrogate marker for the risk of HCC development, in addition to liver biopsy. (HEPATOLOGY 2014;60:1563-1570 
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-M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA 1 -M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha-fetoprotein (AFP), WFA 1 -M2BP, and the response to interferon (IFN) therapy. Serum WFA 1 -M2BP levels were significantly increased according to the progression of liver fibrosis stage (P < 0.001). In each distinctive stage of fibrosis (F0-F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA 1 -M2BP. Multivariate analysis identified age >57 years, F4, AFP >20 ng/mL, WFA T he annual incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related cirrhosis ranges from 1% to 7%.
1,2 Therefore, reliable methods for the early identification of liver fibrosis progression and compensated liver cirrhosis are an essential part of an efficient surveillance program for the detection of HCC. 3 Until recently, liver biopsy was considered the gold standard for assessing the severity of liver fibrosis and cirrhosis. 4, 5 Although liver biopsy is generally accepted to be a safe procedure, it can cause discomfort and carries a small risk of life-threatening complications. 6, 7 Recently, an assay for Wisteria floribunda agglutininpositive human Mac-2-binding protein (WFA 1 -M2BP) was reported as a novel, noninvasive, and rapid bedside method to assess liver fibrosis.
8 M2BP has been shown to have multibranching and sialylated N-glycans. WFA is considered to recognize the GalNAc residue of N-glycans and O-glycans or the clustered LacNAc (Gal-GlcNAc) structure. Currently, we are analyzing the glycan structures of WFA 1 -M2BP in detail using mass spectrometry-based technology. 9 Glycans can reflect the differentiation stage of cells, but not necessarily the level of cellular damage, and therefore they can be very effective markers for chronic disease. In the case of hepatitis, glycans are considered to reflect the progression of fibrosis more specifically than viral load. Several reports have identified M2BP as a potential marker of fibrosis progression in proteome study. [10] [11] [12] [13] Kuno et al. were the first to report that a rapid, simple glycan-based immunoassay for WFA 1 -M2BP can quantify fibrosis. 8, 14 On the other hand, we reported that alphafetoprotein (AFP) is a noninvasive predictive marker for the development of HCC in patients infected with HCV, which can be used to complement the information of fibrosis stage. 15 In this report, we evaluated the utility of WFA 1 -M2BP to predict the development of HCC in patients who were infected with HCV.
Patients and Methods
Patients. Between January 1992 and December 2003, 832 patients were determined to be positive for both anti-HCV by a second-or third-generation enzyme-linked immunoadsorbent assay and HCV RNA by polymerase chain reaction (PCR). They underwent liver biopsy guided by ultrasonography at the National Hospital Organization, Nagasaki Medical Center ( Omura, Japan). Among them, 125 (15.0%) patients were excluded from enrollment in this retrospective analysis for the following reasons: (1) positivity for hepatitis B surface antigen (n 5 12); (2) a heavy habitual drinking habit defined by an average daily consumption of >100 g of ethanol (n 5 26); (3) autoimmune hepatitis (AIH), primary biliary cirrhosis, or idiopathic portal hypertension (n 5 8); (4) positive antinuclear antibody (Ab; defined as titer >3203) without the diagnosis of AIH (n 5 8); or (5) a short follow-up period <180 days (n 5 71). The remaining 707 patients were analyzed retrospectively for the incidence of HCC.
For all patients in our cohort, a blood sample was taken on the day of the liver biopsy at our hospital. All samples were preceded to separate serum and stored at 220˚C. At the time of blood withdrawal, all patients underwent liver biopsy. Their medical histories had been recorded, along with the results of routine tests for blood cell counts, liver biochemical parameters, and markers for HCV infection at the time of ultrasound (US)-guided liver biopsy and at regular intervals thereafter. Complete blood cell counts and biochemical tests were performed using automated procedures in the clinical pathological laboratories of our hospital.
Staging of Hepatic Fibrosis. Liver biopsies were taken by fine-needle aspiration (16G or 18G sonopsy) guided by US. Liver tissue specimens were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. They were evaluated for the stage of hepatic fibrosis by a pathologist according to the criteria of Desmet et al. 16 Measurement of WFA 1 -M2BP. WFA 1 -M2BP quantification was measured based on a lectin-Ab sandwich immunoassay using the fully automatic immunoanalyzer, HISCL-2000i (Sysmex Co., Hyogo, Japan). 8 The measured values of WFA 1 -M2BP conjugated to WFA were indexed with the obtained values using the following equation: 14 HCV RNA, HCV Core Antigen, and HCV Genotypes. HCV RNA was determined by reversetranscriptase (RT)-PCR using a commercial kit (Amplicor HCV; Roche Diagnostic Systems, Basel, Switzerland). HCV core antigen was determined using the Lumispot Eiken HCV antigen assay (Eiken Chemicals, Tokyo, Japan). HCV core antigen levels were classified into low and high with a cutoff at 1,000 fmol/ mL. 17 Genotypes of HCV were determined by RT-PCR with genotype-specific primers (HCV RNA core genotype; Roche Diagnostics, Tokyo, Japan). 18 Interferon Therapy. During the observation period, 373 of the 707 (52.8%) patients received interferon (IFN) monotherapy, pegylated (Peg)-IFN monotherapy, or combination therapy with IFN plus ribavirin (RBV) or Peg-IFN plus RBV. Sustained virological response (SVR) was defined as the absence of detectable HCV RNA at the end of 6 months or more of treatment, whereas patients who failed to meet these criteria were judged as having non-SVR. There was no relapse of viremia after 6 months among the SVR patients.
Diagnosis of HCC. Patients were followed up by hematological and biochemical tests at an interval of 1-12 months. Diagnostic imaging by US, computed tomography (CT), and magnetic resonance imaging (MRI) were performed in most patients. HCC was diagnosed by typical vascular patterns on CT, MRI, and angiography or by fine-needle biopsy of spaceoccupying lesions detected in the liver.
Ethical Considerations. Informed consent was obtained from each patient included in the study, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in the a priori approval by the institution's human research committee.
Statistical Analysis. Continuous variables (platelet counts, albumin, total bilirubin, aspartate aminotransferase [AST], alanine aminotransferase [ALT], AFP, HCV core antigen, and WFA 1 -M2BP) were dichotomized with respect to the median value or clinically meaningful values in the multivariate analysis. To estimate the cumulative risk of developing HCC, KaplanMeier's method and the log-rank test were used. Cox's proportional hazards regression analysis was performed to evaluate risk factors for HCC. Regression analysis was performed to calculate Spearman's rank-correlation coefficient. Kruskal-Wallis' analysis of variance (ANOVA), followed by the Games-Howel's posthoc test, was used to assess whether there were any significant differences in terms of fibrosis stages (F0-F1, F2, F3, and F4). The diagnostic performances of WFA 1 -M2BP and AFP for censored development of HCC were assessed by using time-dependent receiver operating characteristic (ROC) curves by examining the area under the ROC (AUROC). 19 Inclusion of variables was assessed using a step-wise selection method. Cochran-Armitage's test for trend was used in the categorical data analysis to assess for the presence of an association between a variable with two categories and a variable with more than three categories. A P value of 0.05 was considered statistically significant. Data analysis was performed with SPSS statistical software (version 22.0; (SPSS, Inc., Chicago, IL) and JMP 10 (SAS Institute Inc., Cary, NC).
Results
Characteristics at Enrollment. The baseline characteristics of the 707 patients at enrollment are summarized in Table 1 . Median age was 57.0 years; 120 (17.0%) patients were diagnosed histologically with liver cirrhosis (fibrosis stage F4) and the remaining 587 had chronic hepatitis (fibrosis stage F0, F1, F2, or F3). The median value of AFP was 6 ng/mL. The median value of WFA We estimated the diagnostic accuracy of WFA 1 -M2BP for detecting stage F3-F4 disease. The AUROC in the prediction of F3 was 0.815 (range, 0.782-0.842). The desired specificity level of 95% was achieved for a 4.0 threshold, and the sensitivity was 40.0%.
We analyzed the proportions of the patients with different WFA 1 -M2BP levels stratified by the fibrosis stage (Fig. 1) Table 2 ), suggesting that fibrosis stage was most closely associated with serum WFA 1 -M2BP value (coefficient b, 0.258; P < 0.001).
Risk Factors for HCC. Cox's regression analysis was performed on several variables, including age, sex, alcohol consumption, IFN therapy during the observation period, biochemical and virological parameters, and serum WFA 1 -M2BP level. The following factors were identified as posing an increased risk for HCC by the univariate analysis: age; response to IFN therapy (no therapy vs. SVR; P < 0.001); fibrosis stage (F3 and F4 vs. F0-F1; P < 0.001); platelet count (<15 3 10 4 /mm 3 vs. 15 3 10 4 /mm 3 ; P < 0.001); albumin (<4.2 vs. 4.2 g/mL; P < 0.001); AST (<53 vs. 53 IU/mL; P < 0.001), ALT (<82 vs. 82 IU/mL; P 5 0.035), and AFP levels (20 and 6-20 vs. <6 ng/ mL; P < 0.001); HCV genotype (1b vs. non-1b; P 5 0.025); and serum WFA 1 -M2BP level (4 and 1-4 vs. <1; P < 0.001). Multivariate analysis was performed on these factors (Table 3 ) and the following were identified as independent risk factors: fibrosis stage (F4); AFP (20 ng/mL); age (57 years); response to IFN therapy (no therapy vs. SVR); and WFA 1 -M2BP (1-4 and 4) . Development of HCC. During the follow-up period, HCC developed in 110 (15.6%) patients. Of Figure 3 shows the relation between the cumulative incidence of HCC and WFA 1 -M2BP levels, stratified by the fibrosis stage. In patients with fibrosis stage F0-F1, there were significant differences in HCC incidence between those with WFA 1 -M2BP levels of 1-4 and those with levels of <1 (P < 0.01) and between those with WFA 1 -M2BP levels of 4 and those with levels of <1 (P < 0.01). In patients with fibrosis stage F2-F3, there were significant differences in HCC incidence between those with WFA 1 -M2BP levels of 1 and those with levels of >4 (P < 0.01) and between those with WFA 1 -M2BP levels of 1-4 and those with levels of >4 (P < 0.001). In patients with fibrosis stage F4, there were significant differences in HCC incidence between those with WFA 1 -M2BP levels of 1-4 and those with levels of >4 (P < 0.05). As with 
Discussion
Liver biopsy has long been considered the gold standard for assessment of hepatic fibrosis, [20] [21] [22] [23] and the Metavir 24 and Desmet et al. 16 staging systems are most commonly used. A higher degree of liver fibrosis is known to be the strongest risk factor for hepatocarcinogenesis in hepatitis C patients. 1, 20 However, it also has its limitations for the staging of fibrosis because of the heterogeneous distribution of fibrosis in the liver, 25 and liver biopsy is an invasive procedure with 1 -M2BP level, 4, 1-4, and <1, respectively. Incidence rate differed significantly among the three groups (P < 0.001, by the log-rank test), increasing in accord with WFA associated morbidity (pain, bleeding, or hemobilia). 26 For these reasons, patients are often reluctant to undergo this invasive procedure and instead choose one of several noninvasive methods available for assessing the degree of liver fibrosis.
Nevertheless, in the past, no significant progress was made in the development of noninvasive biomarkers to guide clinical usage. WFA 1 -M2BP was recently validated as a liver fibrosis glycobiomarker with a fully automated immunoassay. 8 In the present study, we assessed the performance of the WFA 1 -M2BP assay in comparison with liver fibrosis stage and several serum markers, and, based on the results, we estimated whether WFA 1 -M2BP is a useful predictor of the development of HCC as well as liver biopsy stage.
The first main finding of our study was that there was a significant correlation between the WFA 1 -M2BP value and the fibrosis stage (Fig. 1) . Moreover, step-wise multiple linear regression analysis showed that liver fibrosis stage was most closely associated with serum WFA 1 -M2BP level. In addition, the degree of necroinflammation had no apparent effect on the WFA 1 -M2BP value. Based on these results, we proposed a clinical management algorithm using a WFA 1 -M2BP assay to predict the fibrosis stage. This approach could be used reliably for the first-line pretherapeutic evaluation of fibrosis in HCV-infected patients. On the other hand, the most widely used noninvasive techniques have recently shifted to physical measurements, such as FibroScan, [27] [28] [29] [30] acoustic radiation force impulse, and real-time strain elastography. FibroScan has the advantages of being rapid and technically simple; however, operator skill affects its diagnostic success rate. Also, stiffness measurements can be difficult to obtain in obese patients and impossible in patients who have ascites. This is regarded as a limitation of transient elastography.
27,28 Therefore, we suggest that FibroScan, in conjunction with an assay of serum fibrosis biomarkers, would improve the diagnostic accuracy.
The second main finding of our study was the significant association between the WFA 1 -M2BP level and the risk of HCC development in hepatitis C patients (Figs. 2 and 3 31 and high serum ALT and AST level. [45] [46] [47] Our results were consistent with these findings. Among them, liver fibrosis stage was the strongest prognostic indicator of chronic hepatitis. However, liver biopsy has several disadvantages. In our study, we have shown that the WFA 1 -M2BP value is also a significant risk factor of HCC development independent of these factors. However, even though WFA (Fig. 3) 15 reported that AFP was a noninvasive predictive marker for the development of HCC in this same cohort; furthermore, not only high AFP levels (20 ng/mL), but also slightly elevated AFP levels of between 6 and 20 ng/mL could indicate substantial risks for the development of HCC, complementing the fibrosis stage. Our present study was redesigned by the addition of one parameter (WFA 1 -M2BP). Multivariate analysis did not identify slightly elevated AFP levels (6-20 ng/mL) as an independent risk factor, but did identify both stratified WFA 1 -M2BP levels (1-4 and 4) as independent risk factors. Also, the timedependent AUROC analysis suggested that WFA 1 -M2BP is superior to AFP as a predictor for the development of HCC. These results mean that the WFA 1 -M2BP level is the most reliable noninvasive predictive marker for the development of HCC in patients infected with HCV.
One of the limitations of the present study is that this cohort of 707 patients was analyzed retrospectively. There is thus need of a future study to prospectively analyze the efficacy of WFA 1 -M2BP as a predictor of HCC development.
Another limitation is that the hepatocarcinogenesis of the patients who underwent IFN therapy was not evaluated. In this study, among the patients who achieved SVR (n 5 139), 3 cases developed HCC during the follow-up period. The WFA 1 -M2BP titers were 6.4, 5.6, and 1.5, respectively, in the 3 patients. All 3 cases obtained titers higher than 1, and 2 cases obtained titers higher than 4. This result suggests that patients with a high WFA 1 -M2BP value should be monitored for the development of HCC even after achieving SVR. However, future assessments of the WFA
1
-M2BP values at IFN administration and at posttreatment will be needed to verify this recommendation.
In conclusion, this study revealed an association between WFA 1 -M2BP and the risk of HCC development in chronic hepatitis C patients. The results suggested that the WFA 1 -M2BP assay should not be limited to use as a surrogate for liver biopsy, but rather could be applied as dynamic indicator of the risk of HCC development.
